REGN
REGENERON PHARMACEUTICALS, INC.Company Information
- Company Name
- REGENERON PHARMACEUTICALS, INC.
- CIK
- CIK0000872589
- Category
- Large accelerated filer
- Ticker: Exchange
- REGN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- REGN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-03
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 16,196
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 87,924,085
- Shares outstanding
- 102,800,000
- Ownership
- 85.53%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | -2 | 103 | 104 | 101 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2,456 | 2,963 | 3,118 | 2,506 | 1,996 | 3,090 | 2,488 | 2,012 | 1,921 | 2,602 | 2,730 | 2,152 | ||||||
| Marketable Securities Current | 5,539 | 5,791 | 5,487 | 5,937 | 5,474 | 5,259 | 6,524 | 7,785 | 7,888 | 7,918 | 8,115 | 7,761 | ||||||
| Accounts Receivable Net Current | 6,565 | 5,731 | 5,741 | 5,687 | 5,610 | 5,561 | 6,212 | 6,107 | 5,717 | 5,222 | 5,667 | 5,585 | ||||||
| Inventory Net | 3,084 | 3,104 | 3,201 | 3,254 | 3,206 | 3,192 | 3,087 | 3,018 | 2,874 | 2,715 | 2,581 | 2,562 | ||||||
| Prepaid Expense And Other Assets Current | 802 | 621 | 475 | 596 | 574 | 469 | 349 | 412 | 682 | 415 | 387 | 575 | ||||||
| Assets Current | 18,446 | 18,209 | 18,022 | 17,981 | 16,860 | 17,572 | 18,661 | 19,334 | 19,082 | 18,872 | 19,479 | 18,635 | ||||||
| Marketable Securities Noncurrent | 9,828 | 9,786 | 10,261 | 10,286 | 10,058 | 9,276 | 8,900 | 8,491 | 7,722 | 6,979 | 5,397 | 5,779 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 5,459 | 5,266 | 5,120 | 5,002 | 4,841 | 4,694 | 4,600 | 4,439 | 4,306 | 4,226 | 4,146 | 4,006 | ||||||
| Intangible Assets Net Excluding Goodwill | 1,310 | 1,287 | 1,257 | 1,381 | 1,352 | 1,167 | 1,149 | 1,120 | 1,102 | 1,059 | 1,039 | 1,017 | ||||||
| Deferred Income Tax Assets Net | 4,381 | 4,191 | 4,077 | 3,847 | 3,572 | 3,443 | 3,314 | 3,015 | 2,881 | 2,765 | 2,575 | 2,317 | ||||||
| Other Assets Noncurrent | 2,306 | 2,130 | 1,821 | 1,673 | 1,537 | 1,393 | 1,136 | 1,043 | 994 | 470 | 444 | 410 | ||||||
| Assets | 41,731 | 40,869 | 40,559 | 40,169 | 38,219 | 37,545 | 37,759 | 37,442 | 36,087 | 34,370 | 33,080 | 32,163 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1,159 | 1,027 | 939 | 904 | 724 | 706 | 790 | 497 | 562 | 671 | 607 | 537 | ||||||
| Accrued Liabilities And Other Liabilities | 2,967 | 2,724 | 2,876 | 2,976 | 2,461 | 2,242 | 2,527 | 2,537 | 2,361 | 2,393 | 2,358 | 2,645 | ||||||
| Finance Lease Liability Current | 720 | 720 | - | - | - | - | - | - | - | - | - | - | ||||||
| Contract With Customer Liability Current | 685 | 636 | 553 | 546 | 482 | 619 | 628 | 627 | 586 | 517 | 459 | 417 | ||||||
| Liabilities Current | 5,531 | 5,108 | 4,368 | 4,425 | 3,667 | 3,567 | 3,944 | 3,661 | 3,509 | 3,581 | 3,423 | 3,599 | ||||||
| Long Term Debt Noncurrent | 1,987 | 1,986 | 1,986 | 1,986 | 1,985 | 1,985 | 1,984 | 1,984 | 1,984 | 1,983 | 1,983 | 1,983 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | 720 | ||||||
| Contract With Customer Liability Noncurrent | 220 | 225 | 209 | 219 | 206 | 212 | 186 | 207 | 206 | 186 | 127 | 125 | ||||||
| Other Liabilities Noncurrent | 2,282 | 2,126 | 2,019 | 1,862 | 1,702 | 1,674 | 1,571 | 1,544 | 1,463 | 909 | 854 | 832 | ||||||
| Liabilities | 10,019 | 9,445 | 9,302 | 9,212 | 8,280 | 8,158 | 8,406 | 8,116 | 7,881 | 7,379 | 7,107 | 7,259 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 14,701 | 14,401 | 13,995 | 13,787 | 13,491 | 13,192 | 12,856 | 12,703 | 12,317 | 11,943 | 11,354 | 11,252 | ||||||
| Retained Earnings Accumulated Deficit | 37,621 | 36,424 | 35,797 | 35,046 | 33,680 | 32,384 | 31,673 | 30,755 | 29,415 | 27,982 | 27,260 | 26,101 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -36 | 12 | 78 | 69 | 53 | 29 | -8 | 60 | -70 | -77 | -81 | -177 | ||||||
| Treasury Stock Common Value | -20,575 | -19,414 | -18,613 | -17,944 | -17,285 | -16,218 | -15,167 | -14,192 | -13,456 | -12,857 | -12,560 | -12,271 | ||||||
| Stockholders Equity | 31,711 | 31,424 | 31,257 | 30,958 | 29,939 | 29,388 | 29,354 | 29,326 | 28,206 | 26,991 | 25,973 | 24,904 | ||||||
| Liabilities And Stockholders Equity | 41,731 | 40,869 | 40,559 | 40,169 | 38,219 | 37,545 | 37,759 | 37,442 | 36,087 | 34,370 | 33,080 | 32,163 | ||||||
| Common Class A | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Common Shares | 36 | 35 | 34 | 33 | 32 | 30 | 28 | 27 | 26 | 26 | 26 | 25 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialREGENERON PHARMACEUTICALS, INC. (REGN) — SEC Financial Statements & Analysis
REGENERON PHARMACEUTICALS, INC. (REGN) is a pharmaceutical preparations company, incorporated in NY. REGENERON PHARMACEUTICALS, INC. trades on Nasdaq as: REGN. REGENERON PHARMACEUTICALS, INC. (REGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, REGENERON PHARMACEUTICALS, INC. carries a market cap of $64.03B, a P/E ratio of 14.79x, a P/B ratio of 2.02x, a P/S ratio of 4.12x, an enterprise value of $64.27B, and an EV/EBITDA multiple of 14.70x. On profitability, it posts a gross margin of 91.41%, an operating margin of 24.74%, a net margin of 27.86%, a Return on Equity (ROE) of 14.04%, a Return on Assets (ROA) of 10.83%, and a Return on Invested Capital (ROIC) of 10.31%. Per share, it reports EPS of $42.11, diluted EPS of $40.84, free cash flow per share of $36.58, and a dividend per share of $3.68. Over the trailing year, it posted revenue growth of 9.29% year-over-year, net income growth of -2.91% year-over-year, and EPS growth of -0.74% year-over-year. On the balance sheet, it maintains a current ratio of 3.34x, a quick ratio of 2.63x, working capital of $12.92B, a debt-to-equity ratio of 0.32x, a debt ratio of 0.24, an interest coverage ratio of 69.37x, free cash flow of $3.76B (TTM), and net debt of $240.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $64.03B
- P/E TTM
- 14.79x
- EPS TTM
- $42.11
- P/B TTM
- 2.02x
- ROE TTM
- 14.04%
- ROA TTM
- 10.83%
- Debt To Equity
- 0.32x
- Free Cash Flow TTM
- $3.76B
- Net Revenue TTM Growth 1Y
- 9.29%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is REGENERON PHARMACEUTICALS, INC. in?
REGENERON PHARMACEUTICALS, INC. (REGN) operates in the Pharmaceutical Preparations industry.
What exchange does REGN trade on?
REGENERON PHARMACEUTICALS, INC. (REGN) trades on the Nasdaq.
Where is REGENERON PHARMACEUTICALS, INC. incorporated?
REGENERON PHARMACEUTICALS, INC. is incorporated in NY.
When was REGENERON PHARMACEUTICALS, INC. (REGN)'s most recent SEC filing?
REGENERON PHARMACEUTICALS, INC. (REGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is REGN's market cap?
REGENERON PHARMACEUTICALS, INC. (REGN) has a market capitalization of $64.03B as of 2026-06-30.
What is REGN's P/E ratio?
REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month P/E ratio is 14.79x as of 2026-06-30.
What is REGN's EPS (earnings per share)?
REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month EPS is $42.11 as of 2026-06-30.
What is REGN's ROE (return on equity)?
REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month Return on Equity (ROE) is 14.04% as of 2026-06-30.
What is REGN's ROA (return on assets)?
REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month Return on Assets (ROA) is 10.83% as of 2026-06-30.
What is REGN's ROIC (return on invested capital)?
REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month Return on Invested Capital (ROIC) is 10.31% as of 2026-06-30.
What is REGN's EV/EBITDA?
REGENERON PHARMACEUTICALS, INC. (REGN)'s trailing twelve month EV/EBITDA is 14.70x as of 2026-06-30.